The physiologic underpinning for cardiac resynchronization therapy (CRT) began with Carl Wiggers in 1925. He showed that when contraction of the heart was induced by direct cardiac electrical stimulation, the early phase of contraction of the heart was slowed and myocardial tension developed more gradually.
1 Wiggers explained these findings by differences in the order of excitation of the ventricle. Subsequent studies by a number of investigators highlighted the fact that a left bundle branch block conduction pattern was associated with dyssynchronous contraction that exacerbated left ventricular systolic dysfunction. Few people appreciate the fact that Dr. Morton Mower who was involved in the development of the implantable cardioverter defibrillator 2, 3 also developed the patent for cardiac resynchronization therapy in 1990 4 that was assigned to CPI/Guidant and subsequently licensed to Medtronic.
In 1994, Cazeau et al. reported one patient with widened QRS and advanced heart failure who achieved dramatic improvement with biventricular pacing. 5 Various short-term animal and clinical hemodynamic studies showed significant improvement in cardiac function when both right and left ventricles of a diseased heart with conduction disturbance were preexcited (biventricular pacing), 6 and similar findings were observed recently with univentricular left ventricular stimulation in the compromised heart with conduction block. 7 Central to all these studies was that dyssynchronous contraction associated with disturbed left ventricular conduction improved with direct left ventricular pacing.
A series of large randomized trials including COMPANION, 8 CARE-HF, 9 MADIT-CRT, 10 and RAFT 11 documented the safety and efficacy of biventricular cardiac reynchronization pacing in patients with various degrees of severity of heart failure. All the studies involved patients with wide QRS complexes, with the best results observed in those with left bundle branch block. Cardiac guideline recommendations followed in 2008, 12 with a recent assigned to CPI/Guidant and subsequently licensed to Medtronic. After Thibault et al. initiated their study but before publication in this issue of "narrow" QRS <120ms. The CRT benefit was similar in patients with wide or "n "n nar arro r r w" w" w" Q Q QRS RS RS. It hould be emphasized that the authors put the word narrow in quotes ("narrow") in the title and h hro ro oug ug ugho ho hout ut ut t t the h h p pap ap aper e when referring to QRS <12 2 20m 0m 0ms since many y t t the p pat at atie ie i nts had QRS durations < <10 00 00ms. The au auth th t or ors s co co onc nc nclu lu lude de ded d th th ha at at " "ca ca ardia a ac resy y yn n nchr r ro on niz izat atio ion n th h her rap ap py ma ma ay y be be h h hel el lpf pf pfu ul u i i in n pa pati ti tien en nts ts t w wit it ith h h ec ech h hoc ca card rd dio o ogr gr g ap p phi hi h c c c ev ev evid id iden en nce ce ce o o of f f in n nte te t rv r rve en entr tr ric c cul ul ula ar ar a a and nd nd int nt ntra ra r v v ven nt ntri ri icu cu c la la l r r as as asy yn ync ch chr ro rony ny y a a and n ncomplete l lef ef ft t t bu bu bund nd ndle le e b b bra anc nc nch h h bl bl bloc oc o k" k k .
Circulation, there were several reports of variable CRT efficiacy in heart failure patients with narrow QRS complexes. In a small observational study by Bleeker et al. involving 66 studied patients with low ejection fraction and left ventricular dyssynchrony on tissue doppler imagaing, the 33 patients with QRS <120ms had left ventricular reverse remodeling with CRT comparable to the 33 patients with QRS complex >120ms. 16 A larger randomized trial by Beshai et al.
involved 172 patients with the primary end point an increase in peak oxygen consumption of at least 1.0 ml per kilogram of body weight per minute during cardiopulmonary exercise testing at 6 months after randomization. 17 The CRT-treated patients did not improve peak oxygen consumption when compared to the non-treated control group. The results of this randomized study were not very encouraging that CRT would be beneficial in patients with narrow QRS complexes.
What have we learned from the large MADIT-CRT trial regarding CRT efficacy and QRS duration? CRT was significantly more effective when the QRS duration was >150ms than in the 130 to 149ms range, 10 and female patients were the only ones who achieved significant CRT benefit with QRS of 130 to 149ms. 18 Heart failure patients with left bundle branch block conduction obtained excellent benefit from CRT, and there was no appreciable benefit from CRT in patients with right bundle branch block or intraventricular conduction delay. Wh Wh What at at hav av ve e e we w learned from the large MA AD ADI IT-CRT trial r reg e e ar rdi di din ng ng CRT efficacy and Q QR QRS S duration n? ? CR CR CRT T wa wa was s s si si sign gn gni if ific ican an antl tl t y y m m more e ef ffec ct tiv v ve wh wh when en n t the he h Q Q QR RS RS d d dur urat atio io on n n wa was s s > > >15 15 50m m ms s th th t a a an n n t t the he he 1 1 130 30 t t to o o 14 149m 9m 9ms s ra ra ang ng ge, e, 10 0 an an nd d d fe fe fema ma ale le e p p pat at atie e ent nt n s s w we were e e t the he he on on nly ly ly o o one ne nes s s w wh who o o ac ac chi hi iev ev e ed ed ed sig ig gni ifi fica ca ant t t CRT benefit t w w wit it i h h h QR QR QRS S of f f 1 1 130 30 3 t t to o o 14 14 49m 9m ms. s. s 18 18 18 H H Hea ea eart rt t f f fai ai ailu lu l re re e p p pat at atie ie i nt nt nts s s wi wi with th th l l lef ef eft t t bu bu b nd nd ndle le le b b bra ra ranc n h block damage, and gender), wide QRS complex and left bundle branch block are excellent electrical biomarkers for identification of heart failure patients who are likely to benefit from resynchronization therapy.
